Project Image:
Title of the project:
PREDICT - Biomarker for the treatment of renal cell carcinoma
Identification of biomarkers to predict response and resistance to VEGFR/mTOR inhibitors in renal carcinoma
Project leader:
Prof. Dr. Hansjürgen Volkmer
Project funding:
  • EU FP7 Health two stage
Project management:
  • Europäische Kommission, Brüssel
Funding reference number:

Although a removal of the kidney (nephrectomy) is curative for a significant proportion of patients, about 50% of patients with a diagnosis of kidney cancer will die of the disease. Despite the fact that there has been significant progress in the treatment of advanced disease with the development of drugs targeting VEGF and mTOR signalling during the last years, no predictive biomarkers for these agents exist. The PREDICT consortium compares genomic data from tumours with high throughput-RNAi screens to identify biomarker for the prediction of individual patient response.


The aim of the PREDICT consortium is the identification of predictive biomarkers for individual patient response to renal cancer therapy. During the last years two drugs, sunitinib and everolimus, have been approved for renal cell carcinoma. However, so far, no corresponding biomarkers exist. Sunitinib addresses different tyrosine kinases and its mode of action is anti-angiogenetic. Everolimus is an inhibitor of the mTOR pathway. The approach of the PREDICT consortium is based on the identification of genomic and transcriptomic signatures predicting the response to treatment with one these drugs. To this end, tumour tissue is collected from patients participating in clinical studies with either sunitinib oder everolimus single treatment regimen and RNA-expression, DNA-copy number as well as exon-sequences are determined. These data sets are compared with phospho-kinome-analyses and drug resistance or hypoxia screens using genome-wide siRNA or personalised transcriptome-based shRNA libraries to allow for the identification of biomarkers and molecular mechanisms implicated in intrinsic or acquired drug resistance. Early detection of drug resistance will give RCC patients access to alternative therapies.

Project partners:
  • Bayer Pharma AG
  • Cancer Research UK
  • EPO GmbH
  • Hopital Europeen Georges Pompidou
  • Horizon Discovery
  • Institut Goustave Roussy
  • Royal Marsden Hospital
  • Semmelweis Universität
  • Technische Universität Dänemark
  • Welcome Trust Sanger Institute